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Abstract
Follistatin (FST), a folliculogenesis regulating protein, is found in relatively high concentrations in female ovarian tissues. FST
acts as an antagonist to Activin, which is often elevated in human ovarian carcinoma, and thus may serve as a potential
target for therapeutic intervention against ovarian cancer. The breast cancer susceptibility gene 1 (BRCA1) is a known tumor
suppressor gene in human breast cancer; however its role in ovarian cancer is not well understood. We performed
microarray analysis on human ovarian carcinoma cell line SKOV3 that stably overexpress wild-type BRCA1 and compared
with the corresponding empty vector-transfected clones. We found that stable expression of BRCA1 not only stimulates FST
secretion but also simultaneously inhibits Activin expression. To determine the physiological importance of this
phenomenon, we further investigated the effect of cellular BRCA1 on the FST secretion in immortalized ovarian surface
epithelial (IOSE) cells derived from either normal human ovaries or ovaries of an ovarian cancer patient carrying a mutation
in BRCA1 gene. Knock-down of BRCA1 in normal IOSE cells demonstrates down-regulation of FST secretion along with the
simultaneous up-regulation of Activin expression. Furthermore, knock-down of FST in IOSE cell lines as well as SKOV3 cell
line showed significantly reduced cell proliferation and decreased cell migration when compared with the respective
controls. Thus, these findings suggest a novel function for BRCA1 as a regulator of FST expression and function in human
ovarian cells.
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Introduction
Ovarian cancer is one of the leading gynecological cancers in
the United States with 22,280 estimated new cases and 15,500
deaths in 2012 (http://www.cancer.gov/cancertopics/types/
ovarian; Assessed on February, 2012). High mortality rates for
ovarian cancer are mainly attributed to the late stage diagnosis of
disease; almost 60–65% of ovarian cancer cases are diagnosed
when cancer has already metastasized beyond the confines of the
ovarian tissue. Early detection of ovarian cancer is shown
significantly increase patient life expectancy to as high as 85%
[1]. Thus, there is a need to develop biomarkers that can be
helpful in detecting ovarian cancer in early stages of the disease.
Most ovarian cancers occur within the ovarian surface epithelium
(OSE) and hence investigations using OSE cells derived from both
normal individual and ovarian cancer patients are critical to
elucidate the etiology of human ovarian cancer. Interestingly, only
5–10% of women with ovarian cancer have inherited genetic
mutations in tumor suppressor genes such as BRCA1 and BRCA2
that predisposes them to breast and ovarian cancer [2,3,4]. In
addition, a genetic linkage cohort study consisting of 214 breast
cancer and breast-ovary cancer families combined, revealed that
90% of the patients harbored mutations in their BRCA1 gene [5].
Moreover, BRCA1 mutation(s) carrier females have about 15 fold
greater risk for developing ovarian cancer when compared to their
non-carrier female counterparts [6,7].
Follistatin (FST), an autocrine single chain glycoprotein, is
expressed in nearly all human tissues such as kidney, brain, uterus,
and breast with the highest concentration found in human ovarian
tissue [8]. Mature, secreted form of FST protein exists in three
isoforms; full length, intermediate and shortest consisting of 315,
303 and 288 amino acids respectively [9]. FST, initially isolated
from follicular fluid was found to interact with Activin, a member
of the transforming growth factor-b (TGF-b) superfamily. Activin
has been shown to regulate cell proliferation, differentiation,
angiogenesis, as well as apoptosis, and thus may be possibly
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of Activin are detected not only in most of the epithelial-origin
ovarian tumors but also in the serum samples collected from the
epithelial ovarian cancer patients. High levels of Activin are
thought to be responsible for promoting disease progression and
are predictive of worst disease prognosis for ovarian cancer
patients [10]. FST binds to Activin in an antagonistic manner and
elevated expression of cellular FST may leads to cytoprotection
role in ovarian cancer patients. A recent study has demonstrated
that transient transfection with wild-type (wt) FST was shown to
inhibit metastasis in small-cell lung cancer cell lines [11]. In
contrast, significantly higher (P,0.05) concentrations of FST have
been reported in ovarian cancer patients when compared with
age-matched healthy volunteers.
Members of the TGF-ß superfamily have been shown to
modulate the growth of normal human ovarian epithelial cells in
vitro [12,13]. Thus, the mutations in TGF-ß receptors or their
intracellular signaling molecules such as SMAD proteins have
been implicated in the development of several cancers
[14,15,16,17,18] including human ovarian cancer [19,20,21].
Another member of the TGF-ß superfamily, inhibin, is a
functional antagonist of activin and has been shown to modulate
growth of normal human ovarian epithelial [22,23]. Inhibins,
produced by human gonads, play crucial role in attenuating
Activin-regulated signaling in human gonodal system [22]. Inhibin
is activated by the presence of a co-factor, beta-glycan, which in
turn competes with activin to bind with the activin receptors (Atria
and ActRIIB), thus antagonizing Activin-regulated signaling
cascade [24]. Furthermore, total inhibin has been suggested as a
potential serum marker for epithelial-origin human ovarian
cancer. Additionally, follistatin related gene protein (FLRG),
which shows a strong homology with FST, and has been shown to
interact and block the function of the TGF-ß superfamily ligands
including Activin, Bone morphogenetic protein (BMP)-2, BMP-6,
BMP-7, and GDF-8. FLRG is primarily expressed in heart, lung,
kidney, and placenta and can be stimulated by TGF-ß, Activin
and SMAD proteins [25]. FLRG expression is reported to be
highly variable in several cancer lines and tissues. One recent study
showed that down-regulation of FLRG inhibits human breast
tumor growth [26].
Several studies have proposed that the targeted therapeutic
strategies, specifically molecular mediators that down-regulate
endogenous Activin expression levels may slow down or inhibit
cancer progression [27]. Thus, a possible role of FST as an Activin
antagonist in the pathogenesis of ovarian cancer requires further
investigation. In this study, we used immortalized ovarian surface
epithelium (IOSE) cells from normal human ovary (IOSE 7576
and IOSE 397) and from an ovarian cancer patient with BRCA1
mutation, IOSE 592F, to investigate the role of BRCA1 in
mediating FST secretion in these cells. We also constructed several
stable BRCA1 clones in SKOV3 ovarian adenocarcinoma cell line
that ectopically express BRCA1 protein (i.e. BRCA1-SKOV3). We
initially performed microarray analysis using BRCA1-SKOV3
clone and control neo clone to identify early biomarkers in ovarian
cancers. Next, we validated our results using real time-PCR
analysis and found that FST and SMAD6 were up-regulated in
BRCA1-SKOV3 clone #19 as well as in all of the IOSE cell lines.
Taken together, these results suggest that the loss or diminished
levels of FST secretion in ovarian cells may potentially serve as a
marker for human ovarian carcinogenesis.
Methods
Expression vectors and reagents
The wild-type (wt) BRCA1 expression plasmid was created by
cloning BRCA1 cDNA into the pcDNA3 vector (Invitrogen,
Carlsbad, CA) using artificially engineered 59 HindIII and 39 NotI
sites [28]. Dimethylsulfoxide (DMSO), ß-mercaptoethanol, and all
other chemicals were obtained from Sigma (St Louis, MO) unless
otherwise stated.
Cell lines and culture conditions
SKOV3 cell line was obtained from the American Type Culture
Collection (Manassas, VA). The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FCS), non-essential amino acids (100 mM), L-
glutamine (5 mM), streptomycin (100 mg/ml) and penicillin
(100 U/ml) (all from Lonza, Inc., Walkersville, MD). The cells
weremaintainedat37uCinahumidifiedatmosphereof95%airand
5% CO2 and sub-cultured twice weekly, using trypsin (Lonza) [29].
Stable BRCA1-SKOV3 clones, as well as empty-vector transfected
(neo) stable clones were generated via transfection with the relevant
vectors followed by selection with Geneticin (Invitrogen).
Immortalized Ovarian Surface Epithelium (IOSE) cells
The immortalized cell lines (IOSE 7576, IOSE 397 and IOSE
592F) were kind gift from Dr.Nelly Auersperg of the Canadian
Ovarian Tissue Bank (University of British Columbia, Vancouver,
Canada). Briefly, ovarian surface epithelial cells were scraped from
human ovarian surface tissue and cultured in 1:1 mixture of
medium 199 (Invitrogen) and MCDB 105 (Sigma) supplemented
with 10% FBS, NaHCO3 (2.2 g/L), L-Glutamine (5 mM),
penicillin (100 U/ml) and streptomycin (100 mg/ml) (all from
Invitrogen). The low-passage cultures of isolated human ovarian
surface epithelium cells were then immortalized by transfecting
with SV40 large-T antigen viral particles [30]. The morphological
characteristics and the growth pattern of IOSE cell lines were seen
to mimic ovarian surface epithelial cells in the extracellular
matrices. Further, IOSE cells exhibit strong morphological
resemblance with the early neoplastic ovarian cells in humans
and thus serve as an excellent model for the in vitro studies focused
on human ovarian carcinogenesis [30,31].
Affymetrix Oligonucleotide Microarrays
Affymetrix microarray analyses were performed at Georgetown
University’s Lombardi Cancer Center Genomics and Epigenomics
Shared Resources core facility. RNA isolation, cDNA synthesis,
gene chip hybridizations, and data analysis were performed as
described earlier [32]. The empty vector and the stable BRCA1
clone in SKOV3 cells that were used to generate microarray data
thoroughly described in our earlier manuscript [32]. The gene
chips used for these experiments were Human Genome U133 Plus
2.0 Array. All microarray data was MIAME (Minimum Informa-
tion About a Microarray Experiment) compliant and the raw data
has been deposited in Gene Expression Omnibus database (GEO)
as describe in our earlier manuscript [32]. The accession number
for this submission is GSE30296. Hierarchical clustering of the
selected genes was done as before [32].
Transient transfections
Proliferating SKOV3 cells were transfected overnight with the
indicated expression vectors (4–6 mg of plasmid DNA per well of a
6-well plate or 20–25 mg per 100 mm dish) using Lipofectamine
2000 (Invitrogen) as described earlier [29,33]. Next day, cells were
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medium for up to 24–48 hr for gene expression.
Small interfering (si) RNA treatments
Asynchronously proliferating cells were pre-treated with gene-
specific siRNA (100 nM for 72 hr) using siPORT Amine (Ambion,
Foster City, CA). The efficiency of knock-down was confirmed via
immunoblotting for the target protein(s). Following siRNAs were
used in this study: control siRNA [ON-TARGET plus Non-
targeting siRNA (Cat# D-001810-01, Dharmacon, Chicago, IL)];
FST specific siRNA was obtained from Santa Cruz Biotechnology,
Santa Cruz, CA; BRCA1-specific siRNA [pool of two custom
synthesized siRNA from Dharmacon (sequences 59R39 CAGC-
TACCCTTCCATCATA and CTAGAAATCTGTTGC-
TATG)]. Both FST and BRCA1 siRNA were targeted against
the ORF of the respective genes.
Semi-quantitative Reverse Transcriptase – Polymerase
Chain Reaction (RT-PCR) analysis
Semi-quantitative RT-PCR assays were performed as described
before [29]. Briefly, cells were treated as indicated above and total
RNA was extracted using the RNase Easy Mini Kit (Qiagen,
Valencia, CA). Aliquots of total RNA (50 ng) were reverse
transcribed using 50 units of Superscript III reverse transcriptase
(Invitrogen) in a reaction volume of 20 ml. Semi-quantitative PCR
amplification was performed using 1 ml aliquot from each sample
of the transcribed cDNA, using hot-start Taq polymerase
(Denville, South Plainfield, NJ). DNA was first denatured for
5 min at 95uC, and then amplified using cycles of 30 sec at 95uC,
30 sec at the specific annealing temperature, and 1 min at 72uC,
with final 10 min incubation at 72uC. The cycle number was
adjusted so that all reactions were within the linear range of PCR
product amplification. The forward and reverse primers used,
annealing temperatures, and expected sizes of the PCR products
are shown in Table 1. Quantitative mean analysis from at least
three independent experiments is represented along with standard
error of measurements (6 SEMs).
Quantitative real-time-PCR (Q-PCR) analysis
The Q-PCR was conducted by the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA)
using SYBR Green PCR Master Mix reagent (Applied Biosystems)
in a 25 ml reaction volume. 10 ng of cDNA samples with
appropriate gene-specific primers were used for each PCR
analysis. Cycle threshold values were automatically adjusted, and
the fold changes for each pair of gene-specific primers were
determined. Q-PCR primers are listed in Table 1 and were
obtained from Real Time Primers, LLC., Elkin Parks, PA.
Western blotting
Cells were treated as indicated and whole cell lysates were
prepared as described previously [34]. Briefly, post-treatment cells
were washed with 1X PBS and lysed using radioimmunoprecip-
itation assay (RIPA) buffer (ROCHE, Indianapolis, IN) supple-
mented with complete Mini, EDTA-free protease inhibitor
cocktail tablet (Roche) on ice for 10 min. The lysed cells were
rocked at 4uC for 20 min, followed by centrifugation at 12,0006g
for 20 min. Aliquots of protein (50 mg) in 4X LDS (lithium dodecyl
sulfate) sample buffer (Invitrogen) were analyzed on the pre-cast
4–12% Bis-Tris (BT) gels (Invitrogen). The fractionated proteins
were then transferred to polyvinylidene fluoride (PVDF) mem-
branes (Millipore, Billerica, MA) and blocked for an hr in 5% non-
fat milk in 1X PBS-Tween 20. Membranes were then incubated
with indicated primary antibodies, and subsequently with species-
specific horseradish peroxidase (HRP)-conjugated secondary
antibody (Santa Cruz). Blotted proteins were visualized using the
enhanced chemiluminescence detection system (Santa Cruz). The
primary antibodies used were: BRCA1 (C-20, Santa Cruz, 1:200);
FST (K-19, Santa Cruz, 1:100); Actin (C-11, Santa Cruz, 1:400),
and Activin (ab89307, Abcam, Cambridge MA, 1:1000).
Follistatin Assay
Quantitative detection of cellular FST levels was performed
using Quantikine Human FST Immunoassay kit (R & D Systems
Inc., Minneapolis, MN) that employs the quantitative sandwich
enzyme immunoassay (ELISA) method. Briefly, a standard curve
was made to quantitate the amount of FST in the culture medium
and cell lysates using known FST standards provided in the kit.
Cells were treated as indicated, and the medium from the treated
cells was diluted 10 times for the assay. Both standards and diluted
samples were pipetted into the wells pre-coated with FST
monoclonal antibody. The immobilized antibody was allowed to
bind to FST present in the samples, followed by the incubation of
an enzyme-linked monoclonal antibody specific for FST in each
well. A substrate solution was added to the wells following
incubation leading to a color development in proportion to the
amount of FST bound during the initial reaction step. The
intensity of the color is measured at dual wavelength (450–
Table 1. Primers, annealing temperatures, and product sizes for PCR amplification.
Gene Direction Primer sequence (59R39) Annealing Temperature Size (bp)
BRCA1 Forward AAC CCC TTA CCT GGA ATC TG 57uC2 2 5
Reverse TCC CTG CTC AGA CTT TCT TC
FST Forward CGG ATC TTG CAA CTG AAT CT 58uC2 0 3
Reverse TCA AAG CCC TCT GAT ACA GC
SMAD6 Forward AAG AGAAAC TCG CTC CAA GT 56uC1 7 7
Reverse GAA AGG CAG GCT TGT TGA TA
ACVR2B Forward CAG CAG ATG TGT CTT TCA CG 58uC2 0 1
Reverse CCT CAA TTC CTG GTT ACC T
Actin Forward TAT CGA GCA CGG CAT CAT CA 58uC2 8 8
Reverse TAA ATG GGC ACG TTG TGG GT
doi:10.1371/journal.pone.0037697.t001
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represented as means 6 SEMs.
Cell migration Assay
Cell migration was assayed using CytoSelect 96-well Cell
Migration Kit, 8 mM, Fluorometric (Cell Biolabs, Inc. San Diego,
CA) as per manufacturer’s instructions, which is based on Boyden
Chamber method. Briefly, treated/untreated cells were suspended
in a serum free culture medium and then plated in the upper
membrane chamber of the cell migration plate. The membrane
chamber containing cells were then placed on the top of the feeder
tray to facilitate cell migration across the membrane. The chemo-
attractant used in the feeder tray was complete cell culture
medium containing 10% FCS. The complete assembly was
incubated at 37uC cell culture incubator for 24 hours. The
migrated cells from each sample was collected from the feeder
tray; lysed using a lysis buffer consisting of fluorescent CyQuannt
GR dye, and the total fluorescence of the migrated cells was
quantified using a Victor 1420 fluorescence microplate reader
(Perkin-Elmer Wallac, Inc., Waltham, MA) at dual wavelength
(480–520 nm). The observed fluorescence units (FU) are directly
proportional to the number of cells migrated; higher the observed
fluorescence higher the cell migration. A standard curve was
constructed for each cell line using an incremental cell density as
per manufacturer’s instructions, and the data obtained from the
standard curve from each cell line (treated/untreated) are
represented as means 6 SEMs.
Cell proliferation Assay
FITC BrdU flow kit from BD Pharmingen (San Jose, CA) was
used to perform the cell proliferation assays with the IOSE cell
lines as per manufacturer’s instructions. Briefly, 10 mM of BrdU
was added to asynchronously growing cells in logarithmic phase
for an hr to pulse the cells. Cells were then fixed and
permeabilized using BD cytofix/Cytoperm buffer (provided in
the kit), and subsequently treated with DNase to expose BrdU.
FITC antibody was then used to detect BrdU, and then the cells
were subjected to a flow cytometer FACSort (Becton Dickinson,
San Jose, CA) and the parameters were set according to the
manufacturer’s instructions. FACS analysis was done in the Flow
Cytometry and Cell Sorting Shared Resources at Lombardi
Cancer Center, Georgetown University. Data obtained were
represented as means 6 SEMs of the percent BrdU labeled cells.
Statistical analysis
The data was statistically analyzed by ‘One way analysis of
variance (ANOVA) via Tukey Test’, which is a pair-wise compar-
ison of the mean responses to the different treatment groups using
SigmaStat statistical software (Ver 3 for windows). A value of
P,0.05 or less was considered significant for all experiments.
Results
Stable expression of BRCA1 in SKOV3 cell line
Unlike breast cancer, there are no well-established guidelines
linking BRCA1 mutations and individual’s predisposition to
developing ovarian cancer. Here, we utilized human ovarian
cancer cell line (SKOV3) as a parent ovarian cancer cell line and
generated several stable clones that ectopically expressed
wtBRCA1 (BRCA1-SKOV3) and its empty background vector,
pcDNA3 (Neo). As seen in Figure 1A, #4, #18, and #19 clones of
BRCA1-SKOV3 demonstrated a significant increase in the
expression of BRCA1 (P,0.05) compared to parental SKOV3
cells as well as corresponding Neo clones. The densitometric
analysis from three independent western blots is shown in
Figure 1B as means 6 standard error of measurements (SEMs).
Thus, generation of SKOV3 sub-cell lines with stable BRCA1
expression would further assist in understanding the effect of
BRCA1 in human ovarian carcinoma.
Differential gene expression due to BRCA1
overexpression in SKOV3 cells
Based on the BRCA1 expression of #19 clone of BRCA1-
SKOV3 (hereafter referred as BRCA1-SKOV3 clone #19) was
selected and paired with #3 of Neo clone (hereafter referred as
Neo clone #3) for the Affymetrix microarray analysis. RNA from
three separate culture passages of BRCA1-SKOV3 clone #19
cells and Neo clone #3 cells was isolated and subjected to the
microarray analysis (see methods for details). Next, we constructed
a hierarchical clustering of gene expression that were significantly
(P,0.05) altered in the BRCA1-SKOV3 clone #19 cells and
compared with the Neo clone #3 cells. We observed over 10 fold
up-regulation in 274 genes and more than 4 fold down-regulation
in 279 genes for BRCA1-SKOV3 clone #19 cells when compared
with Neo clone #3 (see Table S1 as well as corresponding heat
map in Figure S1). Using this microarray data, Ingenuity Pathway
analysis revealed that BRCA1 overexpression in SKOV3 cells
(BRCA1-SKOV3 clone #19) modulates several critically impor-
tant signaling and metabolic pathways (see Table S2 for the up-
regulated genes and Table S3 for the down-regulated genes in
BRCA1-SKOV3 clone #19). The list of genes was further
narrowed down to selected 40 genes based on about 3 fold-change
in the expression levels when compared to control, and with
significant p values (P,0.05). The selected groups of genes were
Figure 1. Generation of SKOV3 cell clones. (A) Several stable lines
were created using overexpression of BRCA1 and its background vector,
pcDNA3 in SKOV3 ovarian carcinoma cells. Expression levels of BRCA1
are shown in all cell clones. Parental indicates non-transfected SKOV3
cells only. Densitometric analysis from three independent immunoblots
is given in (B). Error bars are SEMs. * represents P,0.05 (compared to
parental).
doi:10.1371/journal.pone.0037697.g001
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progression and oxidative stress response, which were of primary
interest for the current study. Hierarchical clustering was redone
using these selected 40 genes dataset for up-regulated (red) or
down-regulated (green) genes due to wtBRCA1 overexpression in
BRCA1-SKOV3 cell clone # 19 (Figure 2). The resultant two
clusters of genes along with their fold-change and p value are
provided in the right panel of Figure 2.
FST, an antagonist of Activin, is responsible for early ovarian
development; however, not much is known about the cellular
regulation of FST in human ovarian tissue. Elevated FST level in
human ovarian cells are suggested to be cytoprotective against
ovarian carcinogenesis. We have observed 51.6 fold higher
expression of FST in BRCA1-SKOV3 clone #19 when
compared with the Neo clone #3 cells. Inhibin was also found
to be significantly (P,0.05) up-regulated (11.6 fold) in BRCA1-
SKOV3 cells. Several studies have suggested the potential role of
inhibin as a biomarker for ovarian cancer of epithelial origin
[35]. A few studies proposing inhibin as a serum marker in
ovarian carcinogenesis revealed that inhibin levels are elevated in
approximately 70–80% of the mucinous type ovarian cancer
patients, and in 15–35% of non-mucinous type epithelial ovarian
cancer cases [36,37]. Studies have further shown that in the post-
menopausal women, total inhibin can be combined with CA-125
for the efficient diagnosis of ovarian epithelial carcinogenesis
[35].
Additionally, we found that several other members of TGF-b
family such as TGF-ß2, TGF-ßR1, TGF-ßR3 and an inhibitory
SMAD, SMAD6, were also up-regulated in BRCA1-SKOV3
clone #19 (Figure 2). Thus, the hierarchical clustering approach
was not only able to confirm number of previously known
potential markers in ovarian cancer but also reveal several other
putative molecular targets that may be of interest for designing
targeted treatment for human ovarian cancer.
Figure 2. Hierarchical gene clustering generated by the Ingenuity Pathway Knowledge Base. A heat map showing significant changes in
a group of selected genes due to overexpression of wtBRCA1 in SKOV3 ovarian carcinoma cells. Three independent microarray analyses were
performed. Two clusters were detected, one due to down-regulation of the genes (green) and other due to up-regulation of the genes (red). Fold
change and p values of the genes in the clusters are given on the right.
doi:10.1371/journal.pone.0037697.g002
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quantitative RT-PCR
We have used RT-PCR to validate the results obtained from the
microarray analysis. Three individual stable clones for each Neo
and BRCA1-SKOV3 cell lines were used to perform semi-
quantitative RT-PCR. We found a significant correlation
(P,0.05) between the microarray and RT-PCR results.
Figure 3A shows representative mRNA expressions of the
indicated genes in all groups of cells. Figure 3B demonstrates
quantitative estimation of the mRNA expressions of all the genes
under investigation based on at least three independent experi-
ments. In all cases, mRNA expression of FST was significantly
(P,0.05) higher in BRCA1-SKOV3 clones when compared to
Neo clones, validating the results observed in microarray analysis,
although it is necessary to note that the degree of fold-change is
variable; possibly due to difference in the sensitivity of these two
techniques. BRCA1-SKOV3 clone #19 demonstrated maximum
up-regulation of BRCA1 among the stable cell lines; hence all the
future experiments were performed using this clone, as shown
above, and was compared with Neo clone #3. In addition, RT-
PCR also confirmed the up-regulation of SMAD6 in the BRCA1-
SKOV3 clone #19 (Figure 3A). Furthermore, we investigated the
effect of transient expression of BRCA1 in the parental SKOV3
cells. The results shown in Figure 3C are consistent with the results
observed in Figure 3A and 3B. FST mRNA expression was found
to be significantly (P,0.05) elevated in BRCA1 overexpressed
SKOV3 cells when compared to the background vector transfect-
ed (pcDNA3) as well as parental SKOV3 cells. In addition, mRNA
expressions of SMAD6 were also elevated in the wtBRCA1
overexpressing cells (Figure 3C). Densitometry of the expression of
the genes of interest from at least three independent experiments
are given in Figure 3D.
BRCA1 regulates FST secretion in SKOV3 ovarian
carcinoma cells
FST is secreted by ovarian follicular fluid in the extracellular
region, and is essential for early ovarian development [38]. In vitro
experiment with cultured ovarian cells exhibit differential levels of
FST secretion in the culture medium depending upon cell
treatments and culture conditions. Thus, a diluted medium serves
a good source to measure the secretion and expression of FST in a
particular cell type. Figure 4A demonstrates a standard curve
obtained with the purified FST protein, which was used to
quantitate the amount of secreted FST in the samples under
investigation. Our results demonstrate that BRCA1 expression in
SKOV3 cells shows approximately 2 fold higher secreted FST
when compared to pCDNA3-transfected cells (Figure 4B). Addi-
tionally, we performed similar quantitative FST assay using
SKOV3 cells where-in BRCA1 was knocked-down by BRCA1-
specific siRNA. Figure 4C showed at least 50% decrease in FST
expression in BRCA1 knock-down cells when compared to cells
treated with control siRNA. Next, we performed the same FST
assay with the stable BRCA1 cell clones in SKOV3 cells as
described earlier. BRCA1-SKOV3 clone #19 cells showed
increased FST secretion than neo clone #3, as expected
(Figure 4D). Moreover, we also investigated the secreted levels of
FST in the stable lines following down-regulation of BRCA1 in the
same. Down-regulation of BRCA1 in either Neo clone #3
(Figure 4E) or BRCA1-SKOV3 clone #19 (Figure 4F) signifi-
cantly (P,0.05) inhibited the secretion of FST in cell culture
medium compared to their respective controls. Protein expression
levels of BRCA1 in all of the above samples are shown in
Figure 4G. Data obtained from this quantitative FST assay
suggests that induction in cellular BRCA1 levels in turn stimulates
extracellular FST secretion in human ovarian cancer cells.
BRCA1 regulates mRNA expression of FST in human
immortalized ovarian surface epithelial (IOSE) cells
Recent statistics on ovarian cancer published by the National
Cancer Institute (NCI) reveal that more than 85% of the ovarian
cancersarisewithintheovariansurfaceepithelial(OSE)cells.OSEis
a single layer squamous epithelium with a few stromal features that
lose its stromal characteristics during neoplastic transformation.
Thus,weexpandedourinvestigationwithcellsderivedfromhuman
OSE,whichwereimmortalizedbySV40Tantigen(IOSE7576and
IOSE 397).In addition, we also used a unique IOSEcell line, IOSE
592F, which was developed from an ovarian cancer patient
harboring mutation in BRCA1 gene [in exon 11, position 3819del5
(GTAAA)].BRCA1expressionlevelsinbothIOSE7576andIOSE
397 cells were manipulated by using either wtBRCA1 plasmid for
overexpression studies or BRCA1-specific siRNA for underexpres-
sion studies. These cells were then subjected to quantitative RT-
PCR as described before (see methods).
IOSE 397 and IOSE 7576 cells that were manipulated to
ectopically express wtBRCA1 showed over 2 fold increase in FST
mRNA expression when compared to pcDNA3-transfected cells
(Figure 5A and 5B). mRNA expression for SMAD6 also showed
induction with the up-regulation of BRCA1 mRNA in these IOSE
cells (Figure 5A and 5B). Interplay between Activin, Inhibin, and
FST were shown to play a part in the development of ovarian
carcinogenesis. Elevated levels of Activin were found in ovarian
tumor cells that subsequently induce cellular proliferation in the
same cells. Conversely, FST act as a regulator by binding to Activin
and antagonizing its tumor promoting function, specifically cell
proliferation. Thus, high expression of FST may possibly result in
low expression of Activin and its receptors. Figure 5A (IOSE 397)
and Figure 5B (IOSE 7576) demonstrate that expression of
ACVR2B, a receptor for Activin, was knocked down with the up-
regulationofBRCA1inthesecellswhencomparedtothepcDNA3-
transfected cells. The down-regulation effect of ACVR2B is
significant (P,0.05) in case of IOSE 7576 cells.
In complement to the overexpression studies, we under-
expressed BRCA1 in both IOSE 7576 and IOSE 397 cells, using
BRCA1-specific siRNA. Cellular mRNA levels of FST were
down-regulated to 60–70% in both IOSE cell lines where BRCA1
expression was knocked down (Figure 5C and Figure 5D) when
compared with the control siRNA transfected cells. On the
contrary, mRNA expression of ACVR2B was elevated with the
down-regulation of BRCA1 in both IOSE 397 (Figure 5C) and
IOSE 7576 (Figure 5D) cells. As expected, the mRNA expression
of SMAD6 was decreased upon BRCA1 knock-down in both
IOSE cells (Figure 5A–D). Thus, our results from IOSE cell lines
as well as BRCA1-SKOV3 cell clone # 19 indicate that changes
in the endogenous BRCA1 levels directly affects the mRNA
expression pattern of FST in human ovarian cells.
Differential secretion of FST by human immortalized
ovarian surface epithelial (IOSE) cells
Subsequently, we demonstrated the effect of FST expression
with respect to BRCA1 expression in IOSE cell lines. Figure 6A
compares the levels of FST secretion by all of the IOSE cells under
investigation. Although both IOSE 7576 and IOSE 397 were
derived from normal human ovarian surface epithelium, they
show different basal level of FST. These differential levels of FST
may be, in part, due to the different genetic background of the
individuals that served as a source for isolating these cells. IOSE-
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medium when compared to both normal IOSE cell lines
(Figure 6A), consistent with our previous observations. Next, we
manipulated the expression of BRCA1 in IOSE cells as before and
performed similar FST assay. As seen in Figure 6B and Figure 6C,
BRCA1 overexpression in IOSE 7576 and IOSE 397 cells
significantly (P,0.05) elevated FST secretion when compared to
vehicle and/or pcDNA3-transfected IOSE cells. We further
investigated whether overexpression of BRCA1 in IOSE 592F
could successfully alter the cellular levels of FST secretion.
Surprisingly, induction of BRCA1 levels by wtBRCA1 failed to
stimulate the secretion of FST in IOSE 592F cells (Figure 6D). In
addition, we investigated the efficiency of FST secretion in both
IOSE 7576 and IOSE 397 where BRCA1 has been knocked down
by BRCA1-specific siRNA. We found a significant (P,0.05)
reduction of FST secretion in BRCA1 down-regulated cells
compared to respective controls supporting the earlier observa-
tions (Figure 6E and Figure 6F).
Furthermore, cells left on the tissue culture plates, after
utilizing the culture medium for quantitative FST assay, were
Figure 3. BRCA1 regulates the mRNA expression of FST. (A) Proliferating stable clones of both Neo (pcDNA3-SKOV3) and wtBRCA1 (BRCA1-
SKOV3) were harvested for semi-quantitative RT-PCR assay as described under ‘Methods’. Bands corresponding to the respective genes are indicated
on the right. (B) The PCR bands from three independent experiments of each indicated genes were quantified by densitometry and mRNA levels were
normalized to Actin. (C) Proliferating SKOV3 cells were transiently transfected either with wtBRCA1 or background pcDNA3 vector and the isolated
RNAs was assayed by semi-quantitative RT-PCR. The results were quantified as above and represented by bar diagram (D). Error bars are SEMs.
*P,0.05 (relative to each controls).
doi:10.1371/journal.pone.0037697.g003
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in a 4–12% BT SDS PAGE, and subsequently immunoblotted
for BRCA1, FST, Activin and Actin. As expected, IOSE 7576
and IOSE 397 cells overexpressing BRCA1 showed increase in
FST expression, whereas knock-down of BRCA1 by BRCA1-
siRNA decreased FST expression in these cells (Figure 7A and
Figure 7B). In contrast, expression of Activin was down-regulated
in BRCA1 overexpressing IOSE 7576 and IOSE 397 cells. On
other hand, Activin expression was up-regulated with knock-
down of BRCA1 and FST (Figure 7A and Figure 7B).
Densitometric analyses based on three independent experiments
are shown in Figure 7C and 7D.
FST regulates cell proliferation and cell motility in human
ovarian cells
We performed two key functional assays namely cell prolifer-
ation assay and cell migration assay using SKOV3 cells as well as
IOSE cells to demonstrate a potential role of FST in ovarian
cancer development. The differential cellular proliferation rates
among IOSE 7576, IOSE 397 and IOSE 592F cells, as observed
by the differential BrdU incorporation in DNA of actively dividing
cells, showed correlation to the differential expression of FST in
these cells indicative of FST’s role in cell proliferation. We have
shown that IOSE-592F, which is an IOSE cell line with a
mutation in BRCA1, has reduced FST expression (Figure 6) and
its proliferation rate was lowest when compared with other two
Figure 4. Effect of ectopic expression of BRCA1 on FST secretion. (A) Standard curve was generated with purified human FST as indicated in
the ‘Methods’, which was used to quantitate unknown FST concentrations in the indicated samples. SKOV3 cells were transfected as before, either for
BRCA1 overexpression (B) or for BRCA1 underexpression (C), and FST assays (see methods) were performed with the diluted culture medium. The
same FST assay was performed with the stable clones as indicated (D) as well as with the stable cells where expression of BRCA1 was knocked down
by BRCA1-siRNA (E–F). Error bars are SEMs. *P,0.05 (relative to each control). Expression of BRCA1 in the above samples is given in (G).
doi:10.1371/journal.pone.0037697.g004
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migration assay to assess the physiological importance of FST in
all of the immortalized OSEs as well as BRCA1 overexpressing
stable clone # 19 in SKOV3 cells. The differential FST expression
pattern in IOSE cell lines is shown in Figure 8B, and was detected
by Western blot analysis. Migratory potential of the IOSE cell
lines is shown in Figure 8C–D. Consistent with cell proliferation
results, IOSE 592F cell line showed significantly (P,0.05) lower
cell migration when compared with IOSE 7576 and IOSE 397
further suggesting the correlation between cell motility and
differential FST status in these cells.
To determine whether FST may be directly contributing to cell
motility, we used an FST knock-down approach using FST-siRNA
and monitor its effect on cell migration. As shown in Figure 9A–F,
cell migration was significantly (P,0.05) decreased not only in
IOSE 7576 and IOSE 397 cells that were treated with FST-siRNA
but also in parental SKOV3 cells treated with FST-siRNA when
compared to their respective controls. Figure 9A–C shows the
direct end-point analysis done by lysing of all the migrated cells in
each case followed by DNA staining and fluorometric analysis. In
contrast, Figure 9D–F demonstrates the number of cells loaded
verses number of cells migrated in each case. As loading for most
of the samples were more or less same, the difference in the
migratory number of the cells reflects the treated/untreated
conditions for each of the cell lines. We further evaluated that the
decrease in cellular migration was not due to change in
morphology of the cells; phase contrast micrographs from all the
cells transfected with control siRNA and FST-siRNA did not
reveal any change in morphology (Figure S2). The efficiency of
FST knock-down in IOSE and SKOV3 cell lines, as detected by
Western blotting, is shown in Figure 9G.
Figure 5. Q-PCR analysis with the immortalized ovarian surface epithelium cells (IOSE). BRCA1 expressions in IOSE cells was modulated
either with wtBRCA1 or BRCA1-siRNA along with appropriate the controls. Total RNA was isolated from all the cells and subjected to real time PCR
analysis. Overexpression of BRCA1 in IOSE 397 (A) and IOSE 7576 (B) cells induce overexpression of FST and SMAD6 but knock down the expression of
ACVR2B. In contrast down-regulation of BRCA1 in IOSE 397 (C) and IOSE 7576 (D) cells, demonstrates the reverse effect. mRNA expression of GAPDH
was used for normalization in each case. Error bars are SEMs. * P,0.05 (relative to each control).
doi:10.1371/journal.pone.0037697.g005
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FST, initially identified in ovarian follicular fluid, was shown to
play a role in cell growth, differentiation and development of
ovarian cells [39,40]. FST is also shown to regulate tumor
progression, angiogenesis, metastasis and apoptosis [11,41,42],
and acts as an antagonist to activin function. Activin is frequently
overexpressed in many cancers including ovarian carcinogenesis
[43,44]. Families with history of breast cancer have 50% increased
risk of developing ovarian cancer due to germ line mutations in
either BRCA1 or BRCA2 tumor suppressor genes. BRCA1,i n
particular, plays a major role in hereditary predisposition for
breast and ovarian cancer susceptibility [45,46]. Even though, the
role of BRCA1 has been established in cases of hereditary breast
and ovarian cancer, its function in ovarian surface epithelial (OSE)
cells needs further assessment. The relation between the OSE cells
and its link to ovarian cancer has expanded recently due to the
ability of cultured OSE to give rise to an ovarian adenocarcinoma
in experimental models [47].
Although FST is mainly found in follicular fluids, its expression
has been detected in many tissues including ovary, kidney, brain,
testis, pancreas, gut, heart, uterus, skeletal muscle, lung, breast,
prostate and pituitary indicating that the function of FST may not
only be confined to the reproductive system [48,49]. BRCA1 is
also expressed at variable levels in a wide range of normal and
pathological human tissues, but mostly it was investigated in
relation to tumor suppression in breast, prostate and ovarian
cancer. Hypothetically, FST overexpression could be beneficial in
treating ovarian tumors with high expression of Activin. Ectopic
expression of BRCA1 in ovarian cells may induce the expression of
FST and this FST expression in turn plays an antagonistic role to
inhibit the cancer promoting function of activin. This phenom-
enon may very well exist in breast and prostate too, but it needs
further investigation. Although this hypothesis may not work with
tumor tissues where FST expression is high when compared to its
normal expression such as in rodent liver tumors [50], but BRCA1
Figure 6. FST assay with IOSE cell line. (A) IOSE 7576, IOSE 397 and IOSE 592F were grown in 10 cm tissue culture plates and the culture medium
was subjected to FST assay as described under ‘Methods’. IOSE 7576 cells (B), IOSE 397 cells (C) and IOSE 592F cells (D) were transiently transfected
with wtBRCA1 for 48 hr and then FST assays were performed with the culture medium. Additionally, BRCA1 expression was knocked down in both
IOSE 7576 (E.) and IOSE 397 (F) cells and then subjected to FST assays. Error bars are SEMs. * P,0.05 (relative to each control).
doi:10.1371/journal.pone.0037697.g006
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e37697Figure 7. Western blot analysis for IOSE cells. IOSE 397 (A) and IOSE 7576 (B) cells were transiently transfected either with wtBRCA1 or BRCA1-
siRNA in each case. Whole cell lysates from the attached cells were fractionated in 4–12% BT gel, and subsequently immunoblotted with the indicated
antibodies. Densitometric analyses of the immunoblots shown above are given in C and D respectively.
doi:10.1371/journal.pone.0037697.g007
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activin expression such as human ovarian cancer.
Several key proteins such as activin, inhibin and FST, besides
the hormones secreted by the pituitary gland, regulate the
process of folliculogenesis. Moreover, activin treatment in
ovarian cancer cell lines was shown to induce increased cell
proliferation, whereas simultaneous FST treatment in such
activin producing cell lines inhibits cell multiplication [10,51].
Activin is shown to play a complex role in cancer progression
and requires careful interpretation with respect to tumorigenesis.
Activin effects are cell-type specific such as proliferative effect of
activin is observed in cultured tumor epithelial cells obtained
from ovarian carcinoma specimens [10], whereas in breast
cancer cell line, MCF-7, activin slows the growth of breast tumor
cells by inducing G0/G1 cell cycle arrest [52]. We studied
mRNA expression of BRCA1, FST, Activin, and SMAD6
proteins in SKOV3 and IOSE cells as well as investigated the
ability of these cells to secrete FST in culture medium with
respect to BRCA1 expression. It is important to note that IOSE
cells were of significant interest since majority of ovarian cancers
arise in ovarian surface epithelium. IOSE 592F cells isolated
from an ovarian cancer patient with a deletion mutation in
BRCA1 secreted significantly low levels of FST in the medium
compared to IOSE 7576 and IOSE 397. The TGF-b
superfamily members, activin and its antagonist FST, act as a
pleiotropic growth factor system that controls cell proliferation,
differentiation, and apoptosis of numerous cell types
[10,51,53,54]. Activin is regulated by TGF-ß members and is a
known stimulator of ovarian carcinogenesis [55,56]. These results
indicate a novel role for the tumor suppressor BRCA1 in ovarian
carcinogenesis.
Figure 8. Cell proliferation and cell migration assay with IOSE cells. (A) Comparative analysis of cell proliferation for IOSE 7576, IOSE 397 and
IOSE 592F cell lines. (B) Western blot analysis showing FST levels for IOSE 7576, IOSE 397 and IOSE 592F cell lines. (C–D) Comparative cell migration
analysis for IOSE 7576, IOSE 397 and IOSE 592F cell lines. Relative fluorescence units (RFU) was measured using all of the migrated cells to the feeder
tray in each sample (C), whereas, analysis of the total number cells loaded in the Boyden chamber verses total number of cells migrated towards the
chemo attractant (10% FBS) in each case is shown in (D).
doi:10.1371/journal.pone.0037697.g008
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proteins, exert an inhibitory effect towards the stimulatory action
of the TGF-ß signaling pathway proteins [57]. Activin, TGF-b1
and BMP-7 are some of the TGF-ß family members known to
modulate SMAD6 expression [58]. Polymorphism study utilizing
ovarian tissues from ovarian cancer patients reveal that mutations
in SMAD6 gene are unlikely to be involved in ovarian
carcinogenesis [59]. However, studies with human SMAD6
demonstrate that SMAD6 partially inhibits the function of activin
during mesoderm formation [60]. Moreover, ectopic expression of
SMAD6 in xenopus embryos was able to entirely block the effects
of BMP-4 signaling [61] leading to developmental defects. It is
known that activin receptor like kinase 2 (ALK2) interacts with
Activin as well as BMPII and TBRII receptors [62], and these
ALK2 interactions are sufficient to induce epithelial-mesenchymal
transmission (EMT) in heart. SMAD6, which is downstream of
ALK2, inhibits EMT in endocardial cells [63] underlining the
importance of SMAD6 in cancer development [26]. Additional
work is required to link the function of SMAD6 with FST in
relation to human ovarian carcinogenesis. Our microarray results
suggest that BRCA1 selectively modulates SMAD6 expression in
ovarian cancer cells. Although there are no reports showing
involvement of SMAD6 in ovarian cancer, the stimulation of
SMAD6 by BRCA1 as observed in our study may be suggestive of
Figure 9. Effect of FST knock down on cell migration. (A–F) Cell migration analysis was performed for IOSE 7576, IOSE 397 and SKOV3 cell lines
that were transfected with either control siRNA or FST-siRNA. Relative fluorescence units (RFU) measured from all the migrated cells in each sample
are shown in A–C, whereas, analysis of the total number cells loaded in the Boyden chamber verses total number of cells migrated towards the
chemo attractant (10% FBS) in each case are shown in D–F. (G) Western blot for IOSE 7576, IOSE 397 and SKOV3 cell lines confirming knock-down of
FST by FST-siRNA.
doi:10.1371/journal.pone.0037697.g009
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further investigation.
To date, regulation of FST gene is not well established.
Recently, bone morphogenetic protein 2 (BMP-2) and forkhead
domain transcription factor L2 (FOXL2) were shown to regulate
FST expression in mouse ovary. Moreover, FST expression was
also shown to be reduced in Wnt4 null mouse during early ovarian
development suggesting positive regulation of FST gene by BMP2,
FOXL2 and Wnt4 [64]. In addition, expression of FST has been
shown to inhibit the up-regulation of Sp6, which is a member of
the Sp family of transcription factors that regulate a wide range of
cellular functions in ameloblasts [65]. FOXL2 is known as a
candidate modulator of smad binding element (SBE1) function.
FOXL2 binds to SMAD3 but not to SMAD2 or SMAD4 [66] and
its association with SMAD6 is not yet established. FST might
modulate ovarian functions by interacting with other family
members of TGF-ß superfamily, especially with bone morphoge-
netic proteins (BMPs). FST interacts with GDF-9, BMP-15, BMP-
6, BMP-4, and BMP-7 within ovarian cells [67,68]. BMPs are
involved in contradictory roles of cancer inhibition as well as
cancer progression. BRCA1 may induce its cytoprotective effect
via modulating the expression of both SMAD6 and FST [69], and
in turn, may induce BMP signaling pathways, which may then
inhibit or delay the progression of ovarian cancer, specifically
epithelial-origin ovarian cancer.
Cellular proliferation, migration, and differentiation are critical
functions of cells that in part, assist in tissue rebuilding and
repair. Activin has been shown to inhibit cell proliferation but
promote cell migration [70,71]. As an antagonist of activin
function, FST expression in cells will have an immense potential
in regulating normal cellular homeostasis. Although FST
originally has been found in the ovarian follicular fluid, recent
reports implicate its role in the regulation of various types of
cancer development and/or prevention. In addition, FST was
also shown to be expressed in the migrating endothelial cells and
simultaneously induce basic fibroblast growth factor (bFGF), thus
demonstrating its role in functional regulation of endothelial cells
[72]. Interplay between wound healing, angiogenesis and
remodeling of molecular matrix serves as an important step for
the progression of any cancer including ovarian carcinogenesis.
Our data demonstrate that down-regulation of FST leads to
reduced cell migration (less wound healing) when compared with
the experimental controls. It may interfere with the normal
cellular process and normal wound healing, delayed or incom-
plete, and thus leading to other factors that eventually determine
the oncogenic transformation of the cells. Studies using prostate
and liver tumors show that genes involving wound healing were
highly activated, whereas tumors originated from breast and
colon cancer displayed mixed results with regards to the
activation of wound healing genes [73]. Role of angiogenesis
has been well documented in the progression of tumor growth
and metastasis. Reports suggest that FST overexpression leads to
induction of angiogenesis and simultaneously demonstrate the
inhibitory action on Activin function in ovarian carcinogenesis.
FST overexpressing tumors showed reduced tumor growth when
compared with mock control [42]. Thus, additional in-vivo
experiments will allow us to justify the possible role of FST as
regulator of ovarian carcinogenesis. In this manuscript, we have
shown that BRCA1 induces FST expression in SKOV3 and
IOSE cells and this FST induction may be mediated by several
other potential genes such as FOXL2, BMP-2, and Sp6.
Moreover, BRCA1 induced FST modulation may be tissue-
specific such as human ovarian tissue. Finally, additional studies
specifically examining the interplay between BRCA1 and FST
and its effect(s) on cellular processes may be helpful in devising
targeted treatment for human ovarian cancer.
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Figure S1 Hierarchical gene clustering generated by the
Ingenuity Pathway Knowledge Base. A heat map showing
significant (P,0.05) changes in a group of 218 genes where the
genes were either up-regulated more than 10 fold or genes were
down-regulated more than 4 fold due to stable overexpression of
BRCA1 in SKOV3 cells (compared to empty pcDNA3 stable
lines). Three independent microarray analyses were performed.
(TIF)
Figure S2 Effect of FST-siRNA treatment on cell mor-
phology. IOSE and SKOV3 cells were transfected with either
control siRNA or FST-siRNA and phase contrast images were
captured through a light microscope using 63X objective. All
photomicrographs are labeled with the cells used in this study. No
change in cell morphology is observed between control-siRNA and
FST-siRNA treated cells for all cell types.
(TIF)
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expression.
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